GLP-1s and Inflammation: What the New 2026 Research Review Suggests.
Study in video: Quintana L, Tabaza N, Kurt B, Kahles F. Anti-inflammatory effects of GLP1 RA drugs. The Journal of Clinical Endocrinology & Metabolism. 2026;111:e2076 to e2085. doi:10.1210/clinem/dgag218.
Are GLP-1 medications doing more than supporting weight loss—could they also reduce inflammation directly? In this episode, nutritionist and author Jessica Brown breaks down a July 2026 review in the Journal of Clinical Endocrinology and Metabolism exploring how GLP-1 receptor activation may influence immune cells, inflammatory signaling pathways (including NF-kappa beta), cytokines, and inflammatory biomarkers. She explains the difference between normal inflammation and chronic dysregulated inflammation, why scientists are investigating immunomodulatory effects beyond metabolic improvements, and what remains unknown about how independent these effects are from weight loss and better metabolic health. Jessica also previews a series covering the review’s findings related to cardiovascular disease, autoimmune disease, sepsis, and neurodegenerative diseases.
00:00 GLP-1s and Inflammation
00:26 Why This Research Matters
02:14 The 2026 Review Study
03:26 Inflammation Basics
04:19 Immune Signaling Explained
06:13 GLP-1 and Immunomodulation
07:51 Key Pathways and Cytokines
08:48 Weight Loss vs Direct Effects
10:49 What Comes Next
11:50 Big Takeaways and Wrap Up
GLP-1s and Inflammation: What the New 2026 Research Review Suggests.
Study in video: Quintana L, Tabaza N, Kurt B, Kahles F. Anti-inflammatory effects of GLP1 RA drugs. The Journal of Clinical Endocrinology & Metabolism. 2026;111:e2076 to e2085. doi:10.1210/clinem/dgag218.
Are GLP-1 medications doing more than supporting weight loss—could they also reduce inflammation directly? In this episode, nutritionist and author Jessica Brown breaks down a July 2026 review in the Journal of Clinical Endocrinology and Metabolism exploring how GLP-1 receptor activation may influence immune cells, inflammatory signaling pathways (including NF-kappa beta), cytokines, and inflammatory biomarkers. She explains the difference between normal inflammation and chronic dysregulated inflammation, why scientists are investigating immunomodulatory effects beyond metabolic improvements, and what remains unknown about how independent these effects are from weight loss and better metabolic health. Jessica also previews a series covering the review’s findings related to cardiovascular disease, autoimmune disease, sepsis, and neurodegenerative diseases.
00:00 GLP-1s and Inflammation
00:26 Why This Research Matters
02:14 The 2026 Review Study
03:26 Inflammation Basics
04:19 Immune Signaling Explained
06:13 GLP-1 and Immunomodulation
07:51 Key Pathways and Cytokines
08:48 Weight Loss vs Direct Effects
10:49 What Comes Next
11:50 Big Takeaways and Wrap Up